Epigenetic mechanisms and therapeutic targeting across diverse malignancies.

Genetic abnormalities cause cancer, a heterogeneous disease. These abnormalities comprise unregulated proliferation, invasion, and metastasis. Transcriptional factors are altered by dysregulation, like DNA methylation, histone modifications, and chromatin remodeling, during tumor formation, progression, and resistance to therapy. These can be reversed and transmitted to subsequent generations. Consequently, tumor suppressor genes can be deactivated without altering DNA sequences. Epigenetic markers have been detected in carcinomas, sarcomas, hematological malignancies, and organ-specific tumors, influencing diagnostic accuracy, prognosis assessment, and treatment strategies. Several epigenetic drugs have been developed due to recent advances in epigenetic research. These include DNA methyltransferase inhibitors, histone deacetylase inhibitors and novel modulators focusing on RNA methylation and chromatin regulation. These pharmaceuticals may facilitate normal gene expression restoration, enhance the sensitivity of treatment-resistant malignancies and improve the efficacy of conventional and immunotherapeutic interventions. Significant challenges, such as tumor heterogeneity, limited target specificity, and off-target toxicity, continue to impede widespread clinical application; others are less challenging. The integration of comprehensive epigenetic profiling with precision oncology frameworks presents transformative opportunities to tailor treatment programs, initiate therapy sooner and enhance long-term patient outcomes. Increasing cancer's epigenome knowledge has led to increased interest in developing personalized, mechanism-based treatments addressing cancer's dynamic and adaptive nature.